There is strong evidence that tuberculin sensitivity cannot be used to evaluate the efficacy of different strains of bacille Calmette-Guérin (BCG). For identifying efficacious strains of BCG and evaluating candidates for new vaccines, the best method is a randomized trial. Simple trials in which newborns would be vaccinated with new and old vaccines in alternate years could demonstrate which vaccine was the better.
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For almost 40 years, all bacille Calmette-Guérin (BCG) strains had to be subcultured at approximately monthly intervals. This was continued until seed lots of freeze-dried vaccines were established in the 1960s. Even now, some subculturing must be done every time a new lot is released for use. As a result, every lot of BCG vaccine in use today must have gone through hundreds of subcultures since its release by Calmette in the 1920s. The opportunities for the evolution of different strains are obvious.
That strains with different characteristics have evolved is evident from a review of the literature. Table 1 shows a number of characteristics in which BCG strains have been reported to differ. It also lists the effects that the different strains have had on animals and humans. In all fairness, it must be noted that differences in tuberculin sensitivity, local ulceration, and adenitis can be affected by dosage and methods of administration, as well as vaccine strain. With all these demonstrated differences among strains, it would be strange if BCG strains did not also vary in their ability to prevent tuberculosis in humans.
For many years, it was believed that the efficacy of a BCG vaccine could be predicted by the frequency and intensity of postvaccinal tuberculin sensitivity. This belief still persists in some quarters despite strong evidence, summarized by Arnold Rich as far back as 1944, that tuberculin sensitivity and the ability to prevent tuberculosis are separate phenomena, although closely associated [13] . More recent evidence has accrued from the results of controlled trials among humans [14] . This is shown in figure 1 . Although there is a slight tendency for the frequency of postvaccinal tuberculin conversions to be associated with degree of protection within lots of a single strain, this is not true among different strains. As shown here, interstrain postvaccinal tuberculin sensitivity does not predict efficacy. In fact, there is a slight negative correlation. This is strong evidence that tuberculin sensitivity cannot be used to evaluate different strains of BCG, and it seems doubtful that it will predict the efficacy of new vaccines.
Animal systems of one sort or another are also used to assess the protective efficacy of different tuberculosis vaccines. Only 1 scientific comparison of animal systems appears to have been reported [15] . Nine laboratories were sent 5 different "vaccines" and were asked only to rank them according to their ability to protect against a subsequent challenge with virulent tubercle bacilli. They were also asked to provide an unvaccinated control group. The 5 "vaccines" included the following: a widely used BCG strain; Mycobacterium avium; saline and oil suspensions of formalin-killed Mycobacterium tuberculosis; and an "extraction residue" presumably prepared from M. tuberculosis. A total of 21 animal systems were used.
The laboratories ranked the 6 treatments (5 "vaccines" plus a control [no treatment prior to challenge]) according to the results of each of the systems they used. Note that differences in the systems could be the animal used, the route and method of inoculation, the method of evaluation, and so forth. As is shown in table 2, BCG did rank best with 12 systems, and the controls fared worst with 13, but there is very little agreement otherwise.
The authors of that study concluded that there was "significant disagreement between the test systems on the rank order of the [5] vaccines" [15] . They did not comment on the fact that BCG ranked worst with one system and that no treatment ranked second best with another. With so much disagreement among systems, it seems that animal systems, as the means of determining protective efficacy, might be feeble reeds on which to lean.
Hope for a definitive answer to the question of BCG efficacy ran high in 1964, when planning began for a trial in the Chingleput area of South India [16] . With nearly 6 years of preparation, it is the best designed and conducted controlled trial of BCG vaccination to date. However, 2 desirable features could not be included. Although South India was appropriate for a trial in an area with a high prevalence of nontuberculous mycobacterial infections, a comparison area with few or no such infections could not be found in India. It would have been desirable to test 1 vaccine that rated highly on all available laboratory evaluations and 1 that was rated poorly. It is understandable that making such an odious comparison was not politically possible for a World Health Organization-sponsored project. As a result, 2 highly rated vaccines were selected; the 1 : 10 dilution of each vaccine may be considered a substitute for less highly rated vaccines.
Despite its excellent design, the failure of the Chingleput trial to show that BCG prevents tuberculosis in a general population has had no noticeable impact on tuberculosis control programs. Perhaps this is, in part, due to the results of post hoc subgroup analysis that showed slight protection among children and adolescents [17] . However, this report ignored the inescapable conclusion that if the overall efficacy is zero, any benefit to one subgroup must be balanced by harm to the remainder.
The failure of the South India trial to demonstrate any substantial protection against tuberculosis emphasized the need to identify an efficacious strain of BCG or to develop a new and better vaccine. Concomitant with this need is the need to evaluate appropriate candidates. There are 3 basic means of doing this in human populations: randomized trials, nonrandomized trials, and observational studies.
The best method of evaluation, when possible, is a randomized trial. Here the exposure is under the control of the investigator, and the similarity of the various treatment groups is maximized by randomization. A further important advantage, often overlooked, is that losses from the treatment groups can be assumed to be similar, minimizing the need for individual follow-up. A placebo control group is desirable but ethically debatable. Although the use of a placebo can be defended because the efficacy of most vaccine strains in current use is not known, some may still feel that the use of a placebo is unethical.
Comparison of 1 vaccine with another should be more acceptable. After all, the major purpose of the search for a new vaccine is to find one that is better than existing strains, not just better than placebo. The results of one such comparison have been reported, although not in sufficient detail for final [14] Indonesian case-control study Japanese better than modified French strain [14] Columbian case-control study Japanese and/or Glaxo better than modified Danish strain [18] . A potential problem of such comparative trials without a placebo is that comparison of 2 equally good vaccines will give the same null result as a comparison of 2 worthless vaccines. Nonrandomized trials are often unacceptable because one cannot be sure that all the factors that affect the incidence of tuberculosis other than the vaccine are the same at 2 different times or in 2 different places. There is one variant that should be seriously considered. It can be applied in any defined political region in which vaccination at birth is routine. If a new vaccine is used 1 year and the old vaccine is used the next year, and this alternation is continued, then comparing tuberculosis incidence among children born in even years with those born in odd years should readily indicate whether one vaccine is appreciably more efficacious than the other. This method approaches true randomization. It requires only that vaccine stocks be changed at close to the same time each year and that childhood tuberculosis can be recognized similarly in odd and even years.
Observational studies, especially case-control studies, have been widely recommended and used as substitutes for controlled trials. To understand the potentially serious problem with these substitutions, it is necessary to engage in a bit of semantics. Efficacy and effectiveness are considered synonyms by most dictionaries. However, in the evaluation field, they have slight differences that are conceptually very important. With respect to vaccination, efficacy means the ability of a vaccine to prevent tuberculosis. Effectiveness means the ability of a vaccination program to prevent tuberculosis. Program effectiveness is a combination of the efficacy of the vaccine being used and whether the program is targeted at high-or low-risk populations.
Unfortunately, there is a general tendency for persons at highest risk to avoid vaccination, for a variety of reasons. If the persons vaccinated in the program come largely from wellto-do, low-risk populations, a case-control study can indicate good effectiveness even when a vaccine with poor efficacy is used. One can only guess how much of a program's effectiveness, as assessed by observational studies, is due to vaccine efficacy and how much is due to the way in which the program is conducted.
There is, however, a situation in which one can tell from an observational study whether one vaccine is more efficacious than another. This is when the vaccine is changed during the study period without changes in other features of the program. Such a situation has been reported in 2 case-control studies (table 4) [14] . In Cali, Columbia, children aged !10 years were eligible for vaccination; 69% aged !1 year in this study were vaccinated. In Jakarta, Indonesia, newborn vaccination was practiced.
In both case-control studies, case patients with tuberculosis and control subjects were aged !15 years. In both areas, program effectiveness was greater during the period when the earlier vaccine was used. If there were no differences in other aspects of the program, differences in effectiveness must be due to differences in vaccine efficacy. Relative efficacy can thus be assessed. In these 2 instances, the vaccine strains used in the earlier periods were more efficacious than those used later.
The results of the 4 studies that showed relative efficacy among humans are summarized in table 5. Since all 4 were started after vaccine strains were preserved by freeze-drying, samples of the vaccines in use at the times of the studies may still exist. If so, the pairs of vaccine strains in table 5 should be used in a wide variety of animal systems under controlled experimental conditions. Systems that showed relative efficacies similar to those observed in the human studies should be used in preliminary evaluations of new vaccines.
The ultimate test will still be controlled trials among humans, preferably several trials in different populations where childhood tuberculosis is still a major problem. Trials patterned after the South India trial would be ideal but may not be feasible. Simpler trials, involving vaccination of newborns with new and old vaccines in alternate years, would be much less expensive, probably more acceptable to host countries, and capable of demonstrating any differences between vaccines that are important enough to warrant a change.
